Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | HTR1D | P28221 | 1/20 | 0.49 |
| ▸ | HTR1B | P28222 | 1/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | GABRG2 | P18507 | 11/20 | 0.46 |
| ▸ | GABRB3 | P28472 | 11/20 | 0.46 |
| ▸ | GABRA5 | P31644 | 11/20 | 0.46 |
| ▸ | GABRA2 | P47869 | 3/20 | 0.46 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.46 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.46 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.43 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL430171 | 0.85 | HTR1A (0.51) | HTR1ACYP2C9HTR1DHTR1BSLC6A4 | |
| SCHEMBL430527 | 0.84 | HTR1A (0.50) | HTR1ACYP2C9HTR1DHTR1BSLC6A4 | |
| SCHEMBL14321045 | 0.80 | HTR1A (0.55) | HTR1ACYP2C9HTR1DHTR1BSLC6A4 | |
| SCHEMBL427036 | 0.78 | HTR1A (0.62) | HTR1ACYP2C9HTR1DHTR1BSLC6A4 | |
| SCHEMBL426964 | 0.77 | HTR1A (0.58) | HTR1ACYP2C9HTR1DHTR1BSLC6A4 | |
| SCHEMBL430212 | 0.76 | HTR1A (0.57) | HTR1ACYP2C9HTR1DHTR1BSLC6A4 | |
| SCHEMBL2233633 | 0.76 | GABRG2 (0.59) | HTR1ACYP2C9HTR1DHTR1BSLC6A4 | |
| SCHEMBL431039 | 0.76 | HTR1A (0.61) | HTR1ACYP2C9HTR1DHTR1BSLC6A4 | |
| SCHEMBL10212296 | 0.74 | HTR1A (0.74) | HTR1ACYP2C9HTR1DHTR1BSLC6A4 | |
| SCHEMBL24632609 | 0.69 | GABRG2 (0.49) | HTR1ACYP2C9HTR1DHTR1BSLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120022056-A1 | FUSED TRICYCLIC DERIVATIVES FOR THE TREATMENT OF PSYCHOTIC DISORDERS | BENTLEY JONATHAN (IT) | 2012-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022056-A1 | FUSED TRICYCLIC DERIVATIVES FOR THE TREATMENT OF PSYCHOTIC DISORDERS | GABBR1, GABRQ, GABRE | HTR1A 7/4885CYP2C9 1185/4885HTR1D 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.